Thus, the three FDA-approved anti-cancer drugs targeting the BRAF mutations, vemurafenib (Zelboraf), dabrafenib (Tafinlar) and trametinib (Mekinist)17, were tested on the PDOs derived from patient #1 as single agents or in combinations. Here, BRAF is linked to cancer.